Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 11/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361536 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30776670 | 1.00 | ALDH1A1 (0.46) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19490752 | 0.88 | PDE4A (0.46) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16865875 | 0.87 | ALDH1A1 (0.50) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16865878 | 0.87 | ALDH1A1 (0.50) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7099805 | 0.87 | ALDH1A1 (0.50) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6423584 | 0.87 | ALDH1A1 (0.50) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2995126 | 0.87 | ALDH1A1 (0.43) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11982806 | 0.83 | ALDH1A1 (0.47) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11982739 | 0.83 | ALDH1A1 (0.47) | ALDH1A1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117587078-A | Preparation method of apremilast drug intermediate | 华中科技大学 | 2024-02-23 | — | — | CN | claimed |
| CN-117587078-A | Preparation method of apremilast drug intermediate | 华中科技大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-117587078-A | Preparation method of apremilast drug intermediate | 华中科技大学 | 2024-02-23 | — | — | CN | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | ALDH1A1 509/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.